First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (FBT) Competitors GBX 1,620.30 +18.40 (+1.15%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines FBT vs. SGE, AVV, AVST, SOPH, TRST, PRSM, KAPE, KNOS, GBG, and LTGShould you be buying First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation stock or one of its competitors? The main competitors of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation include The Sage Group (SGE), AVEVA Group (AVV), Avast (AVST), Sophos Group plc (SOPH.L) (SOPH), Trustpilot Group (TRST), Blue Prism Group (PRSM), Kape Technologies (KAPE), Kainos Group (KNOS), GB Group (GBG), and Learning Technologies Group (LTG). These companies are all part of the "software - application" industry. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation vs. The Sage Group AVEVA Group Avast Sophos Group plc (SOPH.L) Trustpilot Group Blue Prism Group Kape Technologies Kainos Group GB Group Learning Technologies Group First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) and The Sage Group (LON:SGE) are both computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment. Do institutionals & insiders hold more shares of FBT or SGE? 67.0% of The Sage Group shares are held by institutional investors. 1.1% of The Sage Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor FBT or SGE? In the previous week, The Sage Group had 3 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 3 mentions for The Sage Group and 0 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's average media sentiment score of 0.00 beat The Sage Group's score of -0.15 indicating that First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is being referred to more favorably in the media. Company Overall Sentiment First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral The Sage Group Neutral Does the MarketBeat Community prefer FBT or SGE? The Sage Group received 453 more outperform votes than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation when rated by MarketBeat users. However, 66.67% of users gave First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation an outperform vote while only 44.99% of users gave The Sage Group an outperform vote. CompanyUnderperformOutperformFirst Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationOutperform Votes7266.67% Underperform Votes3633.33% The Sage GroupOutperform Votes52544.99% Underperform Votes64255.01% Which has higher valuation and earnings, FBT or SGE? The Sage Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than The Sage Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFirst Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation£870.31K5,501.21N/A-£1.10-1,473.00The Sage Group£2.25B5.71£267M£0.264,961.54 Do analysts rate FBT or SGE? The Sage Group has a consensus price target of GBX 3,918, indicating a potential upside of 203.72%. Given The Sage Group's stronger consensus rating and higher probable upside, analysts clearly believe The Sage Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00The Sage Group 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is FBT or SGE more profitable? The Sage Group has a net margin of 11.87% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. The Sage Group's return on equity of 22.31% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.Company Net Margins Return on Equity Return on Assets First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/A N/A N/A The Sage Group 11.87%22.31%7.58% SummaryThe Sage Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 13 of the 16 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation News Delivered to You Automatically Sign up to receive the latest news and ratings for FBT and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBT vs. The Competition Export to ExcelMetricFirst Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationSoftware IndustryComputer SectorLON ExchangeMarket Cap£4.79B£5.48B£25.52B£1.65BDividend YieldN/A3.15%2.77%11.77%P/E Ratio-1,473.00742.62245.341,629.27Price / Sales5,501.215,147.723,289.54338,475.24Price / Cash3.5417.9735.4537.39Price / Book852.7914.638.012.79Net IncomeN/A£59.40M£675.54M£173.29M7 Day Performance-1.50%-0.54%0.67%-1.76%1 Month PerformanceN/A3.16%6.94%15.52%1 Year Performance9.85%42.73%22.97%26.13% First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBTFirst Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AGBX 1,620.30+1.1%N/A+7.9%£4.79B£870,310.00-1,473.0020Gap UpSGEThe Sage Group1.5663 of 5 starsGBX 1,299-0.7%GBX 3,918+201.6%+9.9%£12.94B£2.25B4,982.6911,326AVVAVEVA GroupN/AGBX 3,219+9,900.0%N/AN/A£9.72B£1.26B-154.766,250Gap UpAVSTAvastN/AGBX 716.60-0.5%N/A+0.0%£7.49B£940.10M3,115.651,800High Trading VolumeSOPHSophos Group plc (SOPH.L)N/AN/AN/AN/A£2.99B£726.90M341.41520TRSTTrustpilot Group0.634 of 5 starsGBX 304.50+3.4%GBX 260-14.6%+108.0%£1.27B£191.59M9,816.67820Positive NewsPRSMBlue Prism GroupN/AGBX 1,274flatN/A+0.0%£1.24B£167.30M-23.681,025High Trading VolumeKAPEKape TechnologiesN/AGBX 285+0.7%N/AN/A£1.22B£623.48M1,900.00850Gap DownKNOSKainos Group2.1112 of 5 starsGBX 811-0.2%GBX 1,200+48.0%-29.2%£1.02B£382.39M2,079.492,953Gap UpGBGGB GroupN/AGBX 356.20flatGBX 395+10.9%+24.2%£898.05M£277.32M-1,896.321,183LTGLearning Technologies Group0.9948 of 5 starsGBX 98.20flatGBX 90-8.4%+20.6%£777.73M£528.05M2,455.005,001 Related Companies and Tools Related Companies The Sage Group Competitors AVEVA Group Competitors Avast Competitors Sophos Group plc (SOPH.L) Competitors Trustpilot Group Competitors Blue Prism Group Competitors Kape Technologies Competitors Kainos Group Competitors GB Group Competitors Learning Technologies Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:FBT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FBT Stock Alerts